• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Erenumab efficacy in highly resistant chronic migraine: a real-life study.

作者信息

Pensato Umberto, Favoni Valentina, Pascazio Alessia, Benini Matteo, Asioli Gian Maria, Merli Elena, Calabrò Calogero, Cortelli Pietro, Pierangeli Giulia, Cevoli Sabina

机构信息

Department of Biomedical and NeuroMotor Sciences (DiBiNeM), Alma Mater Studiorum - University of Bologna Italy, Bologna, Italy.

IRCCS Istituto delle Scienze Neurologiche di Bologna, Via Altura 3, 40139, Bologna, Italy.

出版信息

Neurol Sci. 2020 Dec;41(Suppl 2):457-459. doi: 10.1007/s10072-020-04658-1.

DOI:10.1007/s10072-020-04658-1
PMID:32852684
Abstract
摘要

相似文献

1
Erenumab efficacy in highly resistant chronic migraine: a real-life study.erenumab在高度耐药性慢性偏头痛中的疗效：一项真实世界研究。
Neurol Sci. 2020 Dec;41(Suppl 2):457-459. doi: 10.1007/s10072-020-04658-1.
2
Erenumab in highly therapy-refractory migraine patients: First German real-world evidence.依瑞奈尤单抗治疗重度治疗抵抗性偏头痛患者：首个德国真实世界证据。
J Headache Pain. 2020 Jul 3;21(1):84. doi: 10.1186/s10194-020-01151-0.
3
Efficacy of erenumab 70 mg in chronic migraine: Vicenza experience.70毫克erenumab治疗慢性偏头痛的疗效：维琴察经验
Neurol Sci. 2020 Dec;41(Suppl 2):479-480. doi: 10.1007/s10072-020-04665-2.
4
Erenumab: First Global Approval.依瑞奈尤单抗：全球首次获批。
Drugs. 2018 Jul;78(11):1157-1161. doi: 10.1007/s40265-018-0944-0.
5
Erenumab in 159 high frequency and chronic migraine patients: real-life results from the Bologna Headache Center.依瑞奈尤单抗治疗159例高频慢性偏头痛患者：来自博洛尼亚头痛中心的真实结果
Neurol Sci. 2020 Dec;41(Suppl 2):483-484. doi: 10.1007/s10072-020-04667-0.
6
Erenumab (Aimovig) for Migraine Prophylaxis in Adults.erenumab（Aimovig）用于成人偏头痛的预防。
Am Fam Physician. 2019 Jun 15;99(12):781-782.
7
CGRP Antagonists for the Treatment of Chronic Migraines: a Comprehensive Review.降钙素基因相关肽（CGRP）拮抗剂治疗慢性偏头痛：全面综述。
Curr Pain Headache Rep. 2019 Mar 14;23(5):29. doi: 10.1007/s11916-019-0768-y.
8
European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention.欧洲头痛联合会关于使用作用于降钙素基因相关肽或其受体的单克隆抗体预防偏头痛的指南。
J Headache Pain. 2019 Jan 16;20(1):6. doi: 10.1186/s10194-018-0955-y.
9
Erenumab: A First-in-Class Monoclonal Antibody for Migraine Prevention.依瑞奈单抗：用于偏头痛预防的首创类单克隆抗体。
Ann Pharmacother. 2019 Sep;53(9):933-939. doi: 10.1177/1060028019835166. Epub 2019 Feb 27.
10
Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial.依瑞奈尤单抗治疗药物过度使用性偏头痛的疗效：一项随机试验的亚组分析。
Neurology. 2019 May 14;92(20):e2309-e2320. doi: 10.1212/WNL.0000000000007497. Epub 2019 Apr 17.

引用本文的文献

1
Calcitonin Gene-Related Peptide Monoclonal Antibodies: Key Lessons from Real-World Evidence.降钙素基因相关肽单克隆抗体：来自真实世界证据的关键经验教训。
Brain Sci. 2024 Sep 22;14(9):948. doi: 10.3390/brainsci14090948.
2
Methodological considerations on real-world evidence studies of monoclonal antibodies against the CGRP-pathway for migraine: a systematic review.关于偏头痛 CGRP 通路单克隆抗体的真实世界证据研究的方法学考虑：系统评价。
J Headache Pain. 2023 Jun 22;24(1):75. doi: 10.1186/s10194-023-01611-3.
3
Chronic Migraine as a Primary Chronic Pain Syndrome and Recommended Prophylactic Therapeutic Options: A Literature Review.
慢性偏头痛作为一种原发性慢性疼痛综合征及推荐的预防性治疗选择：文献综述
Life (Basel). 2023 Feb 28;13(3):665. doi: 10.3390/life13030665.
4
Monoclonal Antibodies against Calcitonin Gene-Related Peptide for Migraine Prophylaxis: A Systematic Review of Real-World Data.降钙素基因相关肽单克隆抗体治疗偏头痛预防：真实世界数据的系统评价。
Cells. 2022 Dec 29;12(1):143. doi: 10.3390/cells12010143.
5
Reducing the Burden of Migraine: Safety and Efficacy of CGRP Pathway-Targeted Preventive Treatments.减轻偏头痛负担：CGRP通路靶向预防性治疗的安全性和有效性
J Clin Med. 2022 Jul 27;11(15):4359. doi: 10.3390/jcm11154359.
6
CGRP Targeting Therapy for Chronic Migraine-Evidence from Clinical Trials and Real-world Studies.靶向降钙素基因相关肽治疗慢性偏头痛——来自临床试验和真实世界研究的证据
Curr Pain Headache Rep. 2022 Jul;26(7):543-554. doi: 10.1007/s11916-022-01056-4. Epub 2022 May 14.
7
Migraine Prevention with Erenumab: Focus on Patient Selection, Perspectives and Outcomes.erenumab预防偏头痛：聚焦患者选择、观点与结果。
Ther Clin Risk Manag. 2022 Apr 5;18:359-378. doi: 10.2147/TCRM.S263825. eCollection 2022.
8
Detoxification vs non-detoxification before starting an anti-CGRP monoclonal antibody in medication overuse headache.在药物过度使用性头痛开始使用抗 CGRP 单克隆抗体之前进行解毒与非解毒的比较。
Cephalalgia. 2022 Jun;42(7):645-653. doi: 10.1177/03331024211067791. Epub 2022 Feb 9.
9
Gender Differences in 3-Month Outcomes of Erenumab Treatment-Study on Efficacy and Safety of Treatment With Erenumab in Men.艾瑞司umab治疗3个月结局的性别差异——男性使用艾瑞司umab治疗的疗效和安全性研究
Front Neurol. 2021 Dec 16;12:774341. doi: 10.3389/fneur.2021.774341. eCollection 2021.
10
Real-world evidence data on the monoclonal antibody erenumab in migraine prevention: perspectives of treating physicians in Germany.偏头痛预防中单克隆抗体依瑞奈umab 的真实世界证据数据：德国治疗医生的观点。
J Headache Pain. 2021 Nov 6;22(1):133. doi: 10.1186/s10194-021-01344-1.